Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension
- PMID: 28195070
Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension
Abstract
Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.
Similar articles
-
Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats.Physiol Res. 1996;45(4):311-6. Physiol Res. 1996. PMID: 9085355
-
Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney.Exp Physiol. 1999 Nov;84(6):1095-105. Exp Physiol. 1999. PMID: 10564706
-
Heart remodeling in the hereditary hypertriglyceridemic rat: effect of captopril and nitric oxide deficiency.Ann N Y Acad Sci. 2002 Jun;967:454-62. Ann N Y Acad Sci. 2002. PMID: 12079874
-
Current insights and future perspectives of flavonoids: A promising antihypertensive approach.Phytother Res. 2024 Jun;38(6):3146-3168. doi: 10.1002/ptr.8199. Epub 2024 Apr 14. Phytother Res. 2024. PMID: 38616386 Review.
-
Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent.Clin Exp Pharmacol Physiol. 2018 Aug;45(8):755-766. doi: 10.1111/1440-1681.12942. Epub 2018 May 3. Clin Exp Pharmacol Physiol. 2018. PMID: 29603319 Review.
Cited by
-
Cardiovascular therapeutics: A new potential for anxiety treatment?Med Res Rev. 2022 May;42(3):1202-1245. doi: 10.1002/med.21875. Epub 2022 Jan 6. Med Res Rev. 2022. PMID: 34993995 Free PMC article. Review.
-
Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension.Front Med (Lausanne). 2020 Jul 10;7:325. doi: 10.3389/fmed.2020.00325. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32754607 Free PMC article.
-
Ivabradine and Blood Pressure Reduction: Underlying Pleiotropic Mechanisms and Clinical Implications.Front Cardiovasc Med. 2021 Feb 10;8:607998. doi: 10.3389/fcvm.2021.607998. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33644129 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical